Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.54 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270000 | 1.00 | TYMP (1.00) | TYMPADORA1SLC29A1DNPH1STAT6 | |
| SCHEMBL22458597 | 1.00 | TYMP (1.00) | TYMPADORA1SLC29A1DNPH1STAT6 | |
| SCHEMBL24201469 | 0.93 | TYMP (0.86) | TYMPADORA1SLC29A1 | |
| SCHEMBL22458251 | 0.93 | TYMP (0.86) | TYMPADORA1SLC29A1 | |
| SCHEMBL29649690 | 0.93 | TYMP (0.86) | TYMPADORA1SLC29A1 | |
| SCHEMBL29649671 | 0.93 | TYMP (0.86) | TYMPADORA1SLC29A1 | |
| SCHEMBL8610982 | 0.91 | TYMP (0.83) | TYMPADORA1SLC29A1DNPH1 | |
| SCHEMBL8613000 | 0.91 | TYMP (0.83) | TYMPADORA1SLC29A1DNPH1 | |
| SCHEMBL18044398 | 0.89 | TYMP (0.80) | TYMPADORA1SLC29A1DNPH1 | |
| SCHEMBL29822417 | 0.89 | TYMP (0.80) | TYMPADORA1SLC29A1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| US-20220160747-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL AZOLOPYRIMIDINE HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-05-26 | — | — | US | disclosed |
| EP-3939988-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL AZOLOPYRIMIDINE HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2022-01-19 | — | — | EP | disclosed |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-5750675-A | 2'-\"up\" fluorinated 2'-deoxy-arabinofuranosylpurines | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-05-12 | — | — | US | disclosed |
| US-5525720-A | Synthesis of 2'-\"up\" fluorinated 2'-deoxy-arabinofuranosyl purines | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | TYMP 1/4885ADORA1 857/4885SLC29A1 1761/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | TYMP 1/4885ADORA1 857/4885SLC29A1 1761/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | TYMP 270/4885ADORA1 2055/4885SLC29A1 3671/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | TYMP 4/4885ADORA1 232/4885SLC29A1 1134/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | TYMP 1/4885ADORA1 857/4885SLC29A1 1761/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | TYMP 270/4885ADORA1 2055/4885SLC29A1 3671/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | TYMP 4/4885ADORA1 232/4885SLC29A1 1134/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | TYMP 270/4885ADORA1 2055/4885SLC29A1 3671/4885 |
| US-20220160747-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL AZOLOPYRIMIDINE HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | TP53, MSH2, ENTPD5 | TYMP 30/4885ADORA1 6/4885SLC29A1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.